Dual VEGF/VEGFR inhibition in advanced solid malignancies: Clinical effects and pharmacodynamic biomarkers

Cancer Biology and Therapy

Volumn 15, Issue 8, 2014, Pages 975-981

  Mittal, Kriti ^a   Koon, Henry ^b   Elson, Paul ^a   Triozzi, Pierre ^a   Dowlati, Afshin ^b   Chen, Helen ^c   Borden, Ernest C ^a   Rini, Brian I ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Bevacizumab; Sunitinib; VEGF; VEGFR

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; BEVACIZUMAB; CALGRANULIN B; ENDOCRINE GLAND DERIVED VASCULAR ENDOTHELIAL GROWTH FACTOR; ENDOGLIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; HAPTOGLOBIN; SUNITINIB; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ANTINEOPLASTIC AGENT; GASTROINTESTINAL HORMONE; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; NEUROPEPTIDE; PHARMACOLOGICAL BIOMARKER; PROK2 PROTEIN, HUMAN; PYRROLE DERIVATIVE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADRENAL CANCER; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANGIOSARCOMA; ANOREXIA; ARTICLE; BLEEDING; CANCER PATIENT; CANCER SIZE; CARDIOGENIC SHOCK; CLINICAL ARTICLE; COHORT ANALYSIS; DIARRHEA; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSGEUSIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERAMYLASEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORAL MUCOSITIS; PHASE 1 CLINICAL TRIAL; RESPIRATORY FAILURE; SIDE EFFECT; ST SEGMENT ELEVATION; THORAX PAIN; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; NEOPLASMS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; FEMALE; GASTROINTESTINAL HORMONES; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASMS; NEUROPEPTIDES; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84905510166     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.29187     Document Type: Article

References (59)

1. Epstein RJ. VEGF signaling inhibitors: more proapoptotic than anti-angiogenic. Cancer Metastasis Rev 2007; 26:443-52; PMID:17786538; http://dx.doi.org/10.1007/s10555-007-9071-1
2. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133:275-88; PMID:4332371; http://dx.doi.org/10.1084/jem.133.2.275
3. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972; 175:409-16; PMID:5077799; http://dx.doi.org/10.1097/00000658- 197203000-00014
4. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219:983-5; PMID:6823562; http://dx.doi.org/10.1126/ science.6823562
5. Claffey KP, Brown LF, del Aguila LF, Tognazzi K, Yeo KT, Manseau EJ, Dvorak HF. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996; 56:172-81; PMID:8548760
6. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246:1309-12; PMID:2479987; http://dx.doi.org/10.1126/science. 2479987
7. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246:1306-9; PMID:2479986; http://dx.doi.org/10.1126/science.2479986
8. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-34; PMID:12890841; http://dx.doi.org/10.1056/ NEJMoa021491
9. Rini BI. Sunitinib. Expert Opin Pharmacother 2007; 8:2359-69; PMID:17927489; http://dx.doi.org/10.1517/14656566.8.14.2359
10. Moreno Garcia V, Basu B, Molife LR, Kaye SB. Combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin Cancer Res 2012; 18:3750-61; PMID:22547772; http://dx.doi.org/10.1158/1078-0432.CCR-11-1275
11. Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, et al. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res 2009; 15:6277-83; PMID:19773375; http://dx.doi.org/10.1158/1078-0432.CCR-09-0717
12. Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, Fischer P, Ronnen E, Ishill N, Patil S, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:1432-9; PMID:19224847; http://dx.doi.org/10.1200/JCO.2008. 19.0108
13. Zangari M, Yaccoby S, Pappas L, Cavallo F, Kumar NS, Ranganathan S, Suva LJ, Gruenwald JM, Kern S, Zhan F, et al. A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica 2011; 96:333-6; PMID:20952514; http://dx.doi.org/10.3324/haematol.2010.031302
14. Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Ivy P, Chen HX, Dowlati A, et al. Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. J Clin Oncol 2010; 28:e284-5, author reply e286-7; PMID:20439632; http://dx.doi.org/10.1200/JCO.2009.27.1759
15. Vlaykova T, Laurila P, Muhonen T, Hahka-Kemppinen M, Jekunen A, Alitalo K, Pyrhönen S. Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression. Melanoma Res 1999; 9:59-68; PMID:10338335; http://dx.doi.org/10.1097/00008390-199902000-00008
16. Döme B, Paku S, Somlai B, Tímár J. Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance. J Pathol 2002; 197:355-62; PMID:12115882; http://dx.doi.org/10.1002/path.1124
17. Kashani-Sabet M, Sagebiel RW, Ferreira CM, Nosrati M, Miller JR 3rd. Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol 2002; 20:1826-31; PMID:11919240; http://dx.doi.org/10.1200/JCO.2002. 07.082
18. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20:4368-80; PMID:12409337; http://dx.doi.org/10.1200/JCO.2002.10.088
19. Folkman J. Angiogenesis. Annu Rev Med 2006; 57:1-18; PMID:16409133; http://dx.doi.org/10.1146/annurev.med.57.121304.131306
20. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002; 29(Suppl 16):3-9; PMID:12516032; http://dx.doi.org/10.1053/sonc.2002.37265
21. Postovit LM, Seftor EA, Seftor RE, Hendrix MJ. Influence of the microenvironment on melanoma cell fate determination and phenotype. Cancer Res 2006; 66:7833-6; PMID:16912153; http://dx.doi.org/10.1158/0008-5472.CAN-06-0731
22. Pötgens AJ, Lubsen NH, van Altena MC, Schoenmakers JG, Ruiter DJ, de Waal RM. Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am J Pathol 1995; 146:197-209; PMID:7531947
23. Tsai HM. The molecular biology of thrombotic microangiopathy. Kidney Int 2006; 70:16-23; PMID:16760911; http://dx.doi.org/10.1038/sj.ki.5001535
24. Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 2008; 3:249-77; PMID:18215115; http://dx.doi.org/10.1146/annurev. pathmechdis.3.121806.154311
25. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358:1129-36; PMID:18337603; http://dx.doi.org/10.1056/NEJMoa0707330
26. Zaki KA, Basu B, Corrie P. The role of angiogenesis inhibitors in the management of melanoma. Curr Top Med Chem 2012; 12:32-49; PMID:22196268; http://dx.doi.org/10.2174/156802612798919240
27. Griffioen AW, Mans LA, de Graaf AM, Nowak-Sliwinska P, de Hoog CL, de Jong TA, Vyth-Dreese FA, van Beijnum JR, Bex A, Jonasch E. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res 2012; 18:3961-71; PMID:22573349; http://dx.doi.org/10. 1158/1078-0432.CCR-12-0002
28. Cascone T, Heymach JV. Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword? J Clin Oncol 2012; 30:441-4; PMID:22184396; http://dx.doi.org/10.1200/JCO.2011.38.7621
29. Basu B, Biswas S, Wrigley J, Sirohi B, Corrie P. Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies. Expert Rev Anticancer Ther 2009; 9:1583-98; PMID:19895243; http://dx.doi.org/10.1586/era. 09.135
30. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005; 9:267-85; PMID:15963249; http://dx.doi.org/10.1111/j.1582-4934.2005. tb00355.x
31. Monnier J, Samson M. Prokineticins in angiogenesis and cancer. Cancer Lett 2010; 296:144-9; PMID:20633984; http://dx.doi.org/10.1016/j.canlet.2010.06. 011
32. Shojaei F, Wu X, Zhong C, Yu L, Liang X-H, Yao J, Blanchard D, Bais C, Peale FV, van Bruggen N, et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007; 450:825-31; PMID:18064003; http://dx.doi.org/10.1038/ nature06348
33. Brennecke S, Deichmann M, Naeher H, Kurzen H. Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Res 2005; 15:515-22; PMID:16314737; http://dx.doi.org/10. 1097/00008390-200512000-00006
34. Chua R, Setzer S, Govindarajan B, Sexton D, Cohen C, Arbiser JL. Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma. J Am Acad Dermatol 2009; 60:758-66; PMID:19389518; http://dx.doi.org/10.1016/j.jaad.2009.01.018
35. Dréau D, Foster M, Hogg M, Swiggett J, Holder WD, White RL. Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma. Oncol Res 2000; 12:241-51; PMID:11417749
36. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E, Lokshin AE. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 2007; 13:2422-8; PMID:17438101; http://dx.doi.org/10.1158/1078-0432.CCR-06-1805
37. Helfrich I, Edler L, Sucker A, Thomas M, Christian S, Schadendorf D, Augustin HG. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 2009; 15:1384-92; PMID:19228739; http://dx.doi.org/10.1158/1078-0432.CCR-08-1615
38. Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kähäri VM, Pyrhönen S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 2005; 11:5158-66; PMID:16033831; http://dx.doi.org/10.1158/1078-0432.CCR-04-2478
39. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma. Med Oncol 2008; 25:431-6; PMID:18363112; http://dx.doi.org/10.1007/s12032-008-9058-y
40. Ascierto PA, Leonardi E, Ottaiano A, Napolitano M, Scala S, Castello G. Prognostic value of serum VEGF in melanoma patients: a pilot study. Anticancer Res 2004; 24:4255-8; PMID:15736481
41. Osella-Abate S, Quaglino P, Savoia P, Leporati C, Comessatti A, Bernengo MG. VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course. Melanoma Res 2002; 12:325-34; PMID:12170181; http://dx.doi.org/10.1097/00008390-200208000-00004
42. Straume O, Akslen LA. Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression. Am J Pathol 2002; 160:1009-19; PMID:11891198; http://dx.doi.org/10.1016/S0002-9440(10)64922-X
43. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19:577-83; PMID:11208853
44. Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, Meng YG, Ferrara N. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A 2009; 106:6742-7; PMID:19346489; http://dx.doi.org/10.1073/pnas.0902280106
45. Shojaei F, Ferrara N. Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res 2008; 68:5501-4; PMID:18632597; http://dx.doi.org/10.1158/0008-5472.CAN-08-0925
46. Shojaei F, Singh M, Thompson JD, Ferrara N. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A 2008; 105:2640-5; PMID:18268320; http://dx.doi.org/10. 1073/pnas.0712185105
47. Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, Blanchard D, Bais C, Peale FV, van Bruggen N, et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007; 450:825-31; PMID:18064003; http://dx.doi.org/10.1038/ nature06348
48. Gardizi M, Kurschat C, Riese A, Hahn M, Krieg T, Mauch C, Kurschat P. A decreased ratio between serum levels of the antagonistic angiopoietins 1 and 2 indicates tumour progression of malignant melanoma. Arch Dermatol Res 2012; 304:397-400; PMID:22410864; http://dx.doi.org/10.1007/s00403-012-1228-2
49. Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, Chambers SK, Ghatage P, Pippitt CH Jr., Brown JV 3rd, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 2012; 30:362-71; PMID:22184370; http://dx.doi.org/10.1200/JCO.2010.34.3178
50. Rosen LSMD, Cohen RB, Gordon MS, Goldman JW, Bear IK, Byrnes B, Perea R, Schoenfeld SL, Gollerkeri A. First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2. J Clin Oncol 2010; 28(Suppl):abstr 2524
51. Ugarte-Berzal E, Redondo-Muñoz J, Eroles P, Del Cerro MH, García-Marco JA, Terol MJ, García-Pardo A. VEGF/VEGFR2 interaction downregulates matrix metalloproteinase-9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration. Blood 2010; 115:846-9; PMID:19965686; http://dx.doi.org/10.1182/blood-2009-08-239426
52. Zhang H, Vakil V, Braunstein M, Smith ELP, Maroney J, Chen L, Dai K, Berenson JR, Hussain MM, Klueppelberg U, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005; 105:3286-94; PMID:15618473; http://dx.doi.org/10.1182/blood-2004-06-2101
53. Beerepoot LV, Mehra N, Vermaat JSP, Zonnenberg BA, Gebbink MFGB, Voest EE. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 2004; 15:139-45; PMID:14679134; http://dx.doi.org/10.1093/annonc/mdh017
54. Beerepoot LV, Mehra N, Linschoten F, Jorna AS, Lisman T, Verheul HMW, Voest EE. Circulating endothelial cells in cancer patients do not express tissue factor. Cancer Lett 2004; 213:241-8; PMID:15327840; http://dx.doi.org/10.1016/ j.canlet.2004.04.019
55. Kim HK, Song KS, Kim HO, Chung J-H, Lee KR, Lee Y-J, Lee DH, Lee ES, Kim HK, Ryu KW, et al. Circulating numbers of endothelial progenitor cells in patients with gastric and breast cancer. Cancer Lett 2003; 198:83-8; PMID:12893434; http://dx.doi.org/10.1016/S0304-3835(03)00268-4
56. Gruenwald V, Beutel G, Schuch-Jantsch S, Reuter C, Ivanyi P, Ganser A, Haubitz M. Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib. BMC Cancer 2010; 10:695; PMID:21194438; http://dx.doi.org/10.1186/1471-2407-10-695
57. Triozzi PL, Achberger S, Aldrich W, Singh AD, Grane R, Borden EC. The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon. J Transl Med 2012; 10:241; PMID:23217102; http://dx.doi.org/10.1186/ 1479-5876-10-241
58. Jiang T, Zhuang J, Duan H, Luo Y, Zeng Q, Fan K, Yan H, Lu D, Ye Z, Hao J, et al. CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood 2012; 120:2330-9; PMID:22718841; http://dx.doi.org/10.1182/blood-2012-01-406108
59. Woywodt A, Blann AD, Kirsch T, Erdbruegger U, Banzet N, Haubitz M, Dignat-George F. Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: proposal of a definition and a consensus protocol. J Thromb Haemost 2006; 4:671-7; PMID:16460450; http://dx.doi.org/10.1111/j.1538- 7836.2006.01794.x